NCT05145660View on ClinicalTrials.gov

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
RADIATION

intensity-modulated radiotherapy (IMRT) with reduced-volume

PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f

DRUG

Chemotherapy

Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

All Listed Sponsors
lead

Jun-Lin Yi, MD

UNKNOWN